Literature DB >> 10566154

The potential for gene therapy in pancreatic cancer.

M J Humphreys1, W Greenhalf, J P Neoptolemos, P Ghaneh.   

Abstract

Pancreatic cancer is highly aggressive and is a leading cause of cancer death in the Western world. Currently, there is no effective treatment for this disease; resection is only available to a small fraction of patients and has a marginal effect on overall survival rates. Chemotherapy and radiation also have very limited effects on patient survival. There is clearly a need for new approaches to treatment of such an aggressive disease. Gene therapy is of potential use in the treatment of cancer, and all currently available strategies are discussed with relevance to pancreatic cancer. A key to such strategy is specific delivery and selective gene expression in target cells. Current approaches include replacement of tumor suppressor genes, the use of antisense (AS) oligonucleotides, gene-directed enzyme prodrug therapy (GDEPT), and immunotherapy. The scene is now set for the next phase of development in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566154     DOI: 10.1385/IJGC:26:1:5

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  103 in total

1.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

Authors:  Y Katayose; M Kim; A N Rakkar; Z Li; K H Cowan; P Seth
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

2.  Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.

Authors:  A Block; S H Chen; K Kosai; M Finegold; S L Woo
Journal:  Pancreas       Date:  1997-07       Impact factor: 3.327

3.  Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing.

Authors:  B A Sullenger; T R Cech
Journal:  Nature       Date:  1994-10-13       Impact factor: 49.962

Review 4.  The tumor suppressor protein p16INK4a.

Authors:  M Serrano
Journal:  Exp Cell Res       Date:  1997-11-25       Impact factor: 3.905

5.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

6.  Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells.

Authors:  M Ahonen; A H Baker; V M Kähäri
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

7.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

8.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

Authors:  B E Huber; E A Austin; C A Richards; S T Davis; S S Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

9.  Biodistribution and gene expression of lipid/plasmid complexes after systemic administration.

Authors:  R I Mahato; K Anwer; F Tagliaferri; C Meaney; P Leonard; M S Wadhwa; M Logan; M French; A Rolland
Journal:  Hum Gene Ther       Date:  1998-09-20       Impact factor: 5.695

10.  In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta.

Authors:  G R Peplinski; K Tsung; J B Meko; J A Norton
Journal:  Surgery       Date:  1995-08       Impact factor: 3.982

View more
  5 in total

1.  A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Authors:  M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

Review 2.  Current approaches to novel therapeutics in pancreatic cancer.

Authors:  Corina E Akerele; Irina Rybalova; Howard L Kaufman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

3.  Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma.

Authors:  A I Sarela; C S Verbeke; J Ramsdale; C L Davies; A F Markham; P J Guillou
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

4.  Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors:  Miguel A Trujillo; Michael J Oneal; Julia Davydova; Elizabeth Bergert; Masato Yamamoto; John C Morris
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

5.  Progress in gene therapy for prostate cancer.

Authors:  Kamran A Ahmed; Brian J Davis; Torrence M Wilson; Gregory A Wiseman; Mark J Federspiel; John C Morris
Journal:  Front Oncol       Date:  2012-11-19       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.